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Pembrolizumab is a humanized antibody that
targets the programmed cell death-1 (PD-1) receptor.
It is currently approved by the US Food and Drug
Administration for patients with advanced mela-
noma and metastatic nonesmall cell lung cancer.
As an immune checkpoint inhibitor, pembrolizumab
augments a patient’s immune system against an
underlying malignancy.
Systemic toxicities associated with use of PD-1
inhibitors such as fatigue, pyrexia, chills, and infu-
sion reactions have been commonly reported.1 We
report a case of sarcoidosis flare associated with
pembrolizumab, which is, to our knowledge, the
first reported case of sarcoidosis linked to PD-1
inhibition.CASE REPORT
A 72-year-old woman with refractory, stage IV
Hodgkin lymphoma diagnosed in 2014 was placed
on pembrolizumab, 200 mg intravenously every 3
weeks. Twelve years prior, the patient had gallstone
pancreatitis, and a chest x-ray at that time found
bilateral hilar adenopathy. Subsequent mediastino-
scopy and lymph node biopsy were notable for
sarcoidosis, although the patient was never symp-
tomatic and was never treated.
Approximately 6 months after starting pembroli-
zumab, the patient presented to the dermatology
clinic with slowly enlarging, asymptomatic subcu-
taneous nodules on her arms. Physical examination
found 2 nontender, subcutaneous nodules on the
right extensor forearm without overlying erythema,
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left forearm. Punch biopsy of the larger right forearm
nodule found mild lymphohistiocytic perivascular
dermatitis with a focal, dermal epithelioid granuloma
(Fig 2, A and B). Infectious stains and tissue cultures
were negative. Based on the clinical presentation
and medical history, a diagnosis of cutaneous
sarcoidosis was made.
Pembrolizumab was held for the progressing skin
lesions and a positron emission tomography/
computed tomography scan was performed to
reassess the status of the lymphoma. The imaging
found new bilateral pulmonary parenchymal patchy
ground glass opacities with septal thickening. There
were also new hypermetabolic areas within multiple
bones, including the left side of the scapula (Fig 3,
A), sternum, and the right side of the iliac. Interval
increases in fludeoxyglucose (FDG)-avid medias-
tinal and bilateral hilar lymph nodes (Fig 3, B),
compared with 3 months prior were seen. It was
unclear whether these changes were secondary to
lymphoma or sarcoidosis.
Soon thereafter, the patient had left eye pain, and
evaluation by an ophthalmologist found acute iritis
attributable to sarcoidosis. In addition, she had
dyspnea and was referred to cardiothoracic surgery
for consideration of video-assisted thoracoscopic
surgery to determine the etiology of the dyspnea
and adenopathy. However, the patient declined toNational Medical Center, 1500 East Duarte Road MOB 2001A,
Duarte, CA 91010. E-mail: jcotliar@coh.org.
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Fig 1. Clinical presentation. A, Nontender subcutaneous nodule of right forearm without
overlying erythema while taking pembrolizumab for refractory Hodgkin lymphoma. B,
Resolution of right forearm subcutaneous nodule while not taking pembrolizumab during
course of prednisone.
Fig 2. Microscopic examination. A, Normal epidermis with mild perivascular lymphohistio-
cytic inflammation. B, Focal dermal epithelioid granuloma. (A and B, Hematoxylin-eosin stain;
original magnifications: A, 310; B, 320.)
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made to initiate an empiric trial of prednisone at a
dose of 60 mg orally daily, to see if there would be a
favorable clinical/radiographic response, based on
the presumption that sarcoidosis induced by pem-
brolizumab, and not lymphoma, was the etiologic
culprit for the clinical and imaging features.Shortly after the initiation of prednisone, the left
eye pain and dyspnea resolved, and within 1 month,
the skin nodules resolved (Fig 1, B). Reimaging
performed approximately 3 months after the prior
scans (1 month after starting prednisone) found
complete resolution of the FDG-avid skeletal regions
previously noted (Fig 3, C ) as well as resolution of
Fig 3. Radiographic examination. Positron emission tomography while taking pembrolizumab
shows uptake within left scapula (A), sternum, hilar/mediastinal lymph nodes (B). Resolution
of left scapula lesion (C), sternal lesion, and adenopathy (D) while not taking pembrolizumab
during prednisone course.
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patient’s lymphoma is currently in complete remis-
sion since she stopped taking pembrolizumab for the
last 4 months.DISCUSSION
Early reports of the PD-1 inhibitors pembrolizu-
mab and nivolumab described exacerbation of pso-
riasis for patients with a previous history of skin
disease and de novo development of psoriasis in
patients who lacked both a personal and family
history.2-4 More severe cutaneous toxicities such asStevens-Johnson syndrome have also been
reported.5
A retrospective review of 82 patients treated with
PD-1 inhibitors for metastatic melanoma found that
49% (40 of 82) of treated patients had some form of
adverse cutaneous event, with lichenoid dermatitis
(17%), eczematous dermatitis (17%), and vitiligo
(15%) being the most common dermatoses.6 In an
additional retrospective case series of 83 patients,
pembrolizumab usewas associatedwith skin toxicity
in 42% (35 of 83), with papular eruptions (29%) most
common, followed by pruritus (12%), and hypopig-
mentation (8%).7
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which PD-1 inhibitors are effective in unleashing an
individual’s immune system against an underlying
cancer, would be the exacerbation or de novo
development of autoimmune disorders, cutaneous
and systemic. Although there is evidence that pa-
tients with diseases such as Churg-Strauss can be
treated successfully with PD-1 inhibition for mela-
noma without subsequent flare of their vasculitis,8
there are also cases in which PD-1 inhibitor use has
led to rapid progression of previously stable patients
with autoimmune diseases such as myasthenia
gravis.9 Recent reports of the development of auto-
immune blistering skin disorders such as bullous
pemphigoid from PD-1 blockade provide additional
concerns about the risk of autoimmune sequelae
from immune checkpoint inhibitors.10
Our case is notable beyond the fact that it is, to our
knowledge, the first reported case of sarcoidosis
flare associated with PD-1 blockade. It highlights the
diagnostic difficulty of discerning the etiology of
adverse events that may radiographically mimic the
disease for which the PD-1 inhibitor is being used;
sarcoidosis, like lymphoma, presents with increased
FDG avidity on positron emission tomography/
computed tomography scans. Our patient’s skin
nodules were bothersome, but the acute iritis and
dyspnea necessitated prednisone use, which even-
tually led to the resolution of the clinical and imaging
features. Without tissue confirmation of sarcoid
involving the skin and the development of sarcoidal
iritis, it is conceivable that the mediastinal, pulmo-
nary, and skeletal lesions could have been falsely
attributed to progression of the lymphoma. While
our patient had a history of asymptomatic pulmonary
sarcoidosis, the development of dyspnea, iritis, and
subcutaneous nodules after several months of pem-
brolizumab use implicates PD-1 blockade in the
progression of sarcoidosis in this circumstance.This case highlights the importance of being
mindful of the spectrum of toxicities associated
with PD-1 inhibitors and ensuring that these toxic-
ities don’t obfuscate a favorable clinical response.
More importantly, it should raise awareness that PD-
1 inhibition, although helpful in redeploying an
individual’s immune response against an underlying
malignancy, may exacerbate underlying autoim-
mune conditions such as sarcoidosis, as an unex-
pected consequence.
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